Hansa Biopharma — December 2024
-
Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS. This is an orphan indication, and GBS is an acute disease in patients that tends to become non-ambulatory within weeks rapidly. If approved, Imflifidase will expand into a dynamic market. We increase our base case to SEK 130 from 125 (Bull SEK 220, Bear SEK 15).
-
-
...
Vicore, Cinclus och Hansa Biopharma är aktierna som har störst uppsida på Stockholmsbörsen just nu, enligt analytikerna. Inget av bolagen väntas vara lönsamma 2025. Trots det ser analytikerna stor potential i aktierna – som har en uppsida på 200-400% till analytikernas genomsnittliga riktkurs.
-
Analytikerna ser stor potential i fler Small Cap-aktier än i bolagen på Mid- och Large Cap. Dock är det få aktier på Small Cap som platsar i vår sammanställning. Vi kräver nämligen att bolagen följs av minst tre analytiker, så att inte enskilda riktkurser får allt för stor påverkan.
...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind